Clinical Trial: A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Thyroid Eye Disease
Study Type: INTERVENTIONAL
Official Title: A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
Brief Summary:
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).The primary and secondary objectives of this study are to evaluate the safety, treatment effect, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.
Read more